Oramed Pharmaceuticals

ORMP

Market cap $168M

ORMP Hedge Fund Activity: Q1 2026 in Review

64 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2026, worth a combined $45M — up 21% from $37.2M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ORMP positions and 8 closed out — a net gain of 8 holders — while 19 added to existing stakes and 16 trimmed.

The largest buyer was Mercer Global Advisors, opening a new position worth an estimated $6.48M. The largest seller was Gem Investment Advisors, cutting an estimated $1.22M.

• 64 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2026, up from 57 in Q4 2025.
• Funds reported $45M of Oramed Pharmaceuticals stock for Q1 2026, up 21% quarter-over-quarter.
• 16 funds opened new Oramed Pharmaceuticals positions in Q1 2026 and 8 closed out, a net change of +8 holders.
• The largest Oramed Pharmaceuticals buyer in Q1 2026 was Mercer Global Advisors, an estimated $6.48M added.
• The largest Oramed Pharmaceuticals seller in Q1 2026 was Gem Investment Advisors, an estimated $1.22M sold.

Based on aggregated 13F filings for Q1 2026.